Can targeted therapy cure my cousin’s lung cancer at 46?

Question

Hello doctor,

My cousin is 46 years old and was diagnosed with ALK-positive lung cancer after evaluation for persistent chest discomfort and fatigue. Her scans showed involvement of the lung along with nearby lymph nodes, and molecular testing confirmed an ALK gene rearrangement. Instead of surgery, doctors started her on ALK inhibitor tablets, explaining that targeted therapy may work better for this mutation.

She has shown improvement in symptoms after starting treatment. Please tell me,

Why do some patients with ALK-positive lung cancer receive targeted therapy instead of surgery, even when they are relatively young?
Does the presence of this mutation change the standard treatment approach?

Kindly help.

Answer 1

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

Anaplastic lymphoma kinase (ALK)-positive lung cancer is a type of lung adenocarcinoma in which the cancer cells carry a specific genetic rearrangement involving the ALK gene. This genetic change acts as a driver that allows the tumor cells to grow and multiply. Targeted medicines called ALK inhibitors are designed to block this signal, which is why they can control the cancer very effectively in many patients. When treatment is started, it is quite common to see improvement in symptoms and reduction in tumor activity.

The decision to use targeted therapy instead of surgery usually depends on the stage of the disease rather than the age of the patient. When scans show that the cancer has involved nearby lymph nodes or has spread beyond a very small localized area in the lung, surgery alone may not remove all disease. In such situations doctors prefer treatments that work throughout the body. Targeted therapy tablets circulate in the bloodstream and can treat cancer cells in different locations at the same time.

The presence of an ALK gene rearrangement does change the treatment approach in your cousin’s case. Once this mutation is identified, targeted therapy is often preferred because it directly blocks the mechanism that is driving the cancer’s growth. In clinical practice, many patients like your cousin with this mutation respond well to these medicines, which is why molecular testing has become an important part of evaluating lung adenocarcinoma.

I hope this information helps you.

Feel free to ask further queries.

Thank you.